O | Practitioner's Docket No. 700157-48436

**PATENT** 

IN 2 9 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

path re application of:

Sodroski et al.

Group:

Application No.:

09/446,820

Examiner:

Filed:

November 10, 1998

For:

STABILIZED PRIMATE LENTIVIRUS ENVELOPE

**GLYCOPROTEINS** 

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that the following correspondence:

1. Information Disclosure Statement (3 pgs);

2. Form PTO 1449 (6 pgs);

3. References AA, CA-GX (129 refs.);

4. Return Receipt Postcard;

is on the date shown below being:

#### **MAILING**

X deposited with the United States Postal Service and with sufficient postage as first class mail in a box addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: December 26, 2000

**FACSIMILE** 

transmitted by facsimile to the Patent Trademark Office.

**Mgnature** 

Carline L. Lemoine

(type or print name of person certifying)

JUN 2 9 2004 E

Docket No. 700157-48436

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: S

Sodroski et al.

Group:

Serial No.:

09/446,820

Examiner:

JUL 0 6 2004

Filed:

November 10, 1998

THECH CENTER 160012850

For:

STABILIZED PRIMATE LENTIVIRUS ENVELOPE

**GLYCOPROTEINS** 

Assistant Commissioner for Patents Washington, D.C. 20231

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence is, on the date shown below, being: deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:\_\_\_\_\_

Oarline L. Lemoine

Sir:

### INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

### I. REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

<u>X</u>

(1) within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or

B445257.1

- (2) within three months of the mailing date of the PCT International Search Report; or
- (3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$240.00, is included herein; or
- (4) after the mailing date of a Final Rejection or Notice of
  Allowance but before the payment of the Issue Fee, and the
  requisite Certification, petition, and petition fee are included
  herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

x are enclosed herewith; and
 have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

### FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

Ronald I. Eisenstein (Reg. 30,628)

NIXON PEABODY LLP

101 Federal Street

Boston, MA 02110

(617) 345-6057

Date: December 26, 2000

/	·C	)	F	E	\
,	JUN	2	9	2004	3C165 3





DOCKET NO.: 700157/48436 SERIAL NO.: 09/446,820 APPLICANT(S): Sodroski et al. INFORMATION DISCLOSURE **GROUP NO.:** FILING DATE: 11/10/98 STATEMENT UNITED STATES PATENT DOCUMENTS FILING DATE IF INVENTOR DOCUME EXAM. **SUBCLASS** APPROPRIATE CLASS DATE ASSIGNEE INITIAL NT JUL 0 6 200a NUMBER S AA 45,817,316 Oct. 6, 1998 000ac.13 FOREIGN PATENT DOCUMENTS CLASS SUBCLASS TRANSL COUNTRY DATE DOCUME MOITA NT NUMBER YES/NO BA BB BC BD BE OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) CA Alkhatib, G., et al., Science 272:1955-1958 (1996) CB Allan, JS., et al., Science 228:1091-1093 (1985) CC Altschul, SF., et al., Nucleic Acids Res. 25: 3389-3402 (1997) CD Arendrup, et al., J. AIDS 5:303-307 (1992) Arthos, J., et al., Cell 57:469 (1989) CE Baggioline, M., et al., Adv. Immunol. 55:97-179 (1994) CF CG | Barre-Sinousi, F., et al., Science 220:868-871 (1983) CH Berkower, et al., J. Exp. Med. 170:1681-1695 (1989) Berman, PW., et al., Nature 345:622-625 (1990) CI CJ Binley, J., et al., AIDS Res. Hum. Retroviruses, 14:191-198 (1997) CK | Bolmstedt, A., et al., J. AIDS 12:213-220 (1996) CL Brodsky, MH., et al., J Immunol. 144:3078-3086 (1990)

1

CM Bruck, et al., Vaccine 12:1141-1148 (1994)

01	PEG
JUN 2	9 2004
EZ.	3

0844 PO-14	49	DOCKET NO.: 700157/48436 SERIAL NO.	: ,09/446,820
INFORMATION DISCLOSURE		APPLICANT(S): Sodroski et al.	
STATEMENT		FILING DATE: 11/10/98 GROUP NO.:	## C 4 #88
CN Bullough, P., et al., Nature		371:37-43 (1994)	JUL 0 6 2004
СО	Burton, et al., Science 266:1	024-1027 (1994)	TECHCENTER 1000/A
СР	Cao, J., et al., J. Virol. 71:9	808-9812 (1997)	
CQ	Carr, CM., et al., Cell 73:82	23-832 (1993)	
CR	Chan, DC., et al., Cell 89:20	63-273 (1997)	
CS	Chen, CH., et al., J. Virol. 6	59:3771-3777 (1995)	
CT	Chen, Z., et al., J. Virol. 71	:2705-2714 (1997)	
CU	Cheng-Mayer, C., et al., Sc	ience 240:80-82 (1988)	
CV	Choe, H., et al., Cell 85:113		
CW	Clark, SJ, et al., N. Engl. J.	Med. 324:950-960 (1991)	
CX	Cocchi, F., et al., Nature M	led. 2:1244-1247 (1996)	
CY	Cocchi, F., et al., Science 2	70:1811-1815 (1995)	
CZ	Connor, R., et al., J. Exp. A	Med. 185:628 (1997)	
DA	Connor, RI., et al., J. Virol	. 67:1772-1778 (1993)	
DB		ngl. J. Med. 321:1626-1631 (1989)	
DC	Cordonnier, A., et al., Natu		
DD	D'Souza, et al., J. Infect. L		
DE	Daar, ES., et al., N. Engl.	I. Med. 324:961-964 (1991)	
DF		ad. Sci. USA 87:6574-6578 (1990)	
DG	- · · · ·		•
DH	, ,		
DI	Davidson, et al., Nat. Gene		
DJ			
DK			
DL			
DM			
DN			
DC	Earl, PL., et al., J. Virol. 6	55:2047-2055 (1991)	

011	THE SEL
NUN 2	9 200% E.

	_		
DOCKET NO.:	700157/48436	SERIAL NO.:	09/446,820

FODR 1980 1440	DOCKET NO.: 700157/48436 SERIAL NO.: 09/446,820						
INFORMATION DISCL							
STATEMENT	FILING DATE: 11/10/98 GROUP NO.:						
	al., Proc. Natl. Acad. Sci. USA 87:648-652 (1990)						
	Natura 355:728-730 (1991)						
1 1	et al., Ann. Inter. Med. 124:654-663 (1996)						
	et al., Ann. Inter. Med. 124:654-663 (1996)  al., Science 272:872-877 (1996)						
	al., J. Virol. 62:4414-4419 (1988)						
DU Freed, E.	al., Proc. Natl. Acad. Sci. USA 87:4650-4654 (1990)						
	J. Virol. 66:848-856 (1992)						
	et al., Science 224:500-503 (1984)						
	al., Virology 185:162-168 (1991)						
	et al., J. Neurochem 64:487 (1995)						
DZ Geller, A	et al., Proc Natl. Acad. Sci. U.S.A. 87:1149 (1990)						
EA Geller, A	Geller, AI., et al., Proc Natl. Acad. Sci. U.S.A. 90:7603 (1993)						
	et al., Curr. Opin. Immunol. 6:140-145 (1994)						
EC Girard, e	., Proc. Natl. Acad. Sci. USA 88:542-546 (1991)						
1 1 1	., J. Virol. 66:7538-7542 (1992)						
	Haigwood, et al., AIDS Res. Hum. Retro. 6:855-869 (1990)						
	et al., J. Virol. 66:172-182 (1992)						
	al., N. Engl. J. Med. 321:1621-1625 (1989)						
EH Ho, et a	. Virol. 65:489-493 (1991)						
El Javaher	et al., Science 250:1590-1593 (1990)						
EJ Kang, e	, Proc. Natl. Acad. Sci. USA 88:6171-6175 (1991)						
EK Kaplitt,	G., et al., Nat. Genet. 8:148 (1994)						
	G., et al., J. Virol. 71:4218 (1997)						
	et al., AIDS Res. Hum. Retro. 7:791-798 (1991)						
	, D., et al., <i>Nature London</i> 312:767-68 (1984)						
1	M., et al., Science 237:1351-1355 (1987)						
	et al., Cell 50:975-985 (1987)						
EQ LeGal I	alle, et al., Science 259: 988 (1993)						

/	0	1 /	D	E	8	
PR	RUL	2	9	2004	(F 59)	
(F	>				<u>\$</u> /_	_

FORMS O-144	19	DOCKET NO.: 700157/48436 SERIAL NO.:	09/446,820			
INFORMATION DISCLOSURE		APPLICANT(S): Sodroski et al.				
STATEMENT		FILING DATE: 11/10/98 GROUP NO.:				
ER ]	Leonard, CK., et al., J. Biol.	Chem. 265:10373-10382 (1990)	WI OF ZOOR			
<u> </u>	Liu, R., et al., Cell 86:367-3		TECH CEC.			
1 1		ural Biol. 2:1075-1082 (1995)	TECH CENTER 1000 2000			
	Marcon, L., et al., J. Virol. 7	1:2522-2527 (1997)				
		Acad. Sci. USA 83:9709-9713 (1986)				
	McKeating, et al., J. Virol. 6					
5 1 - 1	McKeating, et al., Virology					
	Moebius, U., et al., J. Exp. A					
·	Moore, et al., J. Virol. 69:10					
FA	Moore, et al., J. Virol. 67:61	36-6151 (1993)				
FB Moore, et al., J. Virol.		53-875 (1993)				
FC	Moore, et al., J. Virol. 69:12	22-133 (1995)	·			
FD	Moore, et al., J. Virol. 70:18	863-1872 (1996)				
FE	Moore, J., et al., J. Virol. 68	:469-484 (1994)				
FF	Moore, J., et al., J. Virol. 68	1:8350-8364 (1994)				
FG	Muster, et al., J. Virol. 67:6	642-6647 (1993)				
FH	Myers, G., et al., "Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences," Los Alamos National Laboratory, (1994)					
FI	Nara, et al., J. Virol. 64:377	9-3791 (1990)				
FJ	Ohno, et al., Proc. Natl. Acc	ad. Sci. USA 88:10726-10729 (1991)				
FK	Olshevsky, U., et al., J. Vire	ol. 64:5701-5707 (1990)				
FL	Peterson, A., et al., Cell 54:	65-72 (1988)	<u>.</u>			
FM	Pinter, A., et al., J. Virol. 63	3:2674-2679	·			
FN	Pollard, S., et al., EMBO J.	11:585-591 (1992)				
FO	Posner, et al., J. Immunol.					
FP		e Medicine 11:1174-1178 (1996)				
FQ	Profy, et al., J. Immunol. 14	14:4641-4647 (1990)	· — — — — — — — — — — — — — — — — — — —			
FR	Roben, P., et al., J. Virol. 6	8:4821-4828 (1994)				

<i>;</i>	01	P	E	5
	JUN 2	9	2004	1 50 m
(E)	`@		,,d	<u>~</u>

. 8			<del></del>	
<b>ORIX</b> TO-14	7,7	CKET NO.: 700157/48		09/446,820
NFORMATIO		PLICANT(S): Sodroski		
TATEMENT		ING DATE: 11/10/98	GROUP NO.:	
FS	Robey, W., et al., Proc. Natl. Ac		-7027 (1986) 	- MY 0.00
FT	Robey, WG., et al., Science 228	:593-595 (1985)		JUL 0 6 2004
FU	Robinson, J., et al., AIDS Res. H	lum. Retro 6:567-580 (	(1990)	UECH COL PA 100072
FV	Rusche, et al., Proc. Natl. Acad.			
FW	Rusche, J., et al., Proc. Natl. Ac	ad. Sci. USA 85:3198-	3202 (1988)	
FX	Ryu, SE., et al., Nature London	348:419-425 (1990)		
FY	Samson, M., et al., Nature 382:	722-725 (1996)		
FZ	Sattentau, Q., et al., J. Exp. Med	1. 174:407-415 (1991)		
GA	Sattentau, Q., et al., J. Virol. 67	:7388-7393 (1993)		
GB	Sawyer, et al., J. Virol. 67:1342	-1349 (1994)		
GC	Schuitemaker, H., et al., J. Viro	<i>l</i> . 66:1354-1360 (1991	)	
GD	Speck, R., et al., J. Virol. 71:71	36-7139 (1997)		
. GE	Starcich, BR., et al., Cell 45:63	7-648 (1986)		
GF	Steimer, et al., Science 254:105	-108 (1991)		
GG	Sullivan, et al., J Virol. 69:4413	3-4422 (1995)		
GH	Thali, et al., J. Virol. 65:6188-6	193 (1991)		
GI	Thali, et al., J. Virol. 66:5635-5	641 (1992)		
GJ	Thali, M., et al., J. Virol. 67:39	78-3988 (1993)		
GK				
GL	Trkola, A., et al., J. Virol. 70:1	100-1108 (1996)		
GM				· ·
GN	Wang, J., et al., Nature London	348:411-418 (1990)		
GO				
GP	Weissenhorn, W., et al., EMBC	J. 15:1507-1514 (199	96)	
GQ				
GR				
GS	<del> </del>			
GT	<del>                                     </del>			

FORM ROO-1	4	19	DOCKET NO.:	700157/4	8436	SERIAL NO.:	09/446,820
MOL		N DISCLOSURE	APPLICANT(S): Sodroski et al.				
STATEMENT		FILING DATE:	11/10/98	GR	OUP NO.:	W 0 6 20	
GU	ı	Wyatt, R., et al., J. Virol. 71	1:9722-9731 (1997)				TECH CENCER MOONE
G\	,	Yang, et al., J. Virol. 69:200	04 (1995)				
GV	- 1	Zhang, L., et al., Nature 38					
G)	7	Zhu, T., et al., Science 261:	1179-1181 (199	3)		·	
	7			·			
						·	
EXAMINER:	لـــ				DA	ATE:	